BioCentury
ARTICLE | Top Story

Scios, Quintiles in Natrecor alliance

January 11, 2001 8:00 AM UTC

QTRN will provide $35 million to commercialize SCIO's Natrecor nesiritide for acute decompensated congestive heart failure, with a $10 million payment to come within six months following launch of the...